Regenxbio(RGNX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Regenxbio
RGNX.US
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I.
1.820 T
RGNX.USMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
E
BiotechnologyIndustry
Industry Ranking361/386
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-196.43%E
    • Profit Margin-330.23%E
    • Gross Margin-970.12%E
  • Growth ScoreE
    • Revenue YoY-43.96%E
    • Net Profit YoY-83.91%E
    • Total Assets YoY-30.36%E
    • Net Assets YoY-92.31%E
  • Cash ScoreD
    • Cash Flow Margin80.61%C
    • OCF YoY-43.96%E
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreE
    • Gearing Ratio93.83%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    16:05 ETREGENXBIO to Participate in Upcoming Investor Conferences

    prnewswire·
    US
    RGNX
    +0.18%
    US
    PBE
    +0.11%
    US
    SBIO
    -1.24%
    prnewswire·
    US
    RGNX
    +0.18%
    US
    PBE
    +0.11%
    US
    SBIO
    -1.24%

    Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

    Market Beat·
    US
    RGNX
    +0.18%
    US
    LABU
    -2.35%
    US
    FBT
    +0.54%
    Market Beat·
    US
    RGNX
    +0.18%
    US
    LABU
    -2.35%
    US
    FBT
    +0.54%

    Morgan Stanley Sticks to Its Buy Rating for RegenXBio (RGNX)

    Tip Ranks·
    US
    RGNX
    +0.18%
    US
    FBT
    +0.54%
    US
    IBB
    +0.10%
    Tip Ranks·
    US
    RGNX
    +0.18%
    US
    FBT
    +0.54%
    US
    IBB
    +0.10%

    Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

    fidelity·
    US
    RGNX
    +0.18%
    US
    IBB
    +0.10%
    US
    BIB
    +0.05%
    fidelity·
    US
    RGNX
    +0.18%
    US
    IBB
    +0.10%
    US
    BIB
    +0.05%

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    benzinga_article·
    US
    QUCY
    -23.64%
    US
    STAA
    +0.90%
    US
    ALP
    -0.36%
    benzinga_article·
    US
    QUCY
    -23.64%
    US
    STAA
    +0.90%
    US
    ALP
    -0.36%
    © 2026 Longbridge｜Disclaimer